ATE266393T1 - Kombinationen von formoterol und fluticasonpropionat für asthma - Google Patents

Kombinationen von formoterol und fluticasonpropionat für asthma

Info

Publication number
ATE266393T1
ATE266393T1 AT00907572T AT00907572T ATE266393T1 AT E266393 T1 ATE266393 T1 AT E266393T1 AT 00907572 T AT00907572 T AT 00907572T AT 00907572 T AT00907572 T AT 00907572T AT E266393 T1 ATE266393 T1 AT E266393T1
Authority
AT
Austria
Prior art keywords
formoterol
asthma
combinations
fluticasone propionate
fluticasone
Prior art date
Application number
AT00907572T
Other languages
English (en)
Inventor
Jeremy Guy Clarke
Henry Luke Danahay
Ian Francis Hassan
Original Assignee
Novartis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10848051&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE266393(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Pharma Gmbh filed Critical Novartis Pharma Gmbh
Application granted granted Critical
Publication of ATE266393T1 publication Critical patent/ATE266393T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT00907572T 1999-02-18 2000-02-16 Kombinationen von formoterol und fluticasonpropionat für asthma ATE266393T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9903759.0A GB9903759D0 (en) 1999-02-18 1999-02-18 Organic compounds
PCT/EP2000/001270 WO2000048587A1 (en) 1999-02-18 2000-02-16 Combinations of formoterol and fluticasone propionate for asthma

Publications (1)

Publication Number Publication Date
ATE266393T1 true ATE266393T1 (de) 2004-05-15

Family

ID=10848051

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00907572T ATE266393T1 (de) 1999-02-18 2000-02-16 Kombinationen von formoterol und fluticasonpropionat für asthma

Country Status (31)

Country Link
US (4) US20020103260A1 (de)
EP (1) EP1152753B1 (de)
JP (1) JP2002537249A (de)
KR (2) KR20010102205A (de)
CN (1) CN1339965A (de)
AR (1) AR022609A1 (de)
AT (1) ATE266393T1 (de)
AU (1) AU758999B2 (de)
BR (1) BR0008276A (de)
CA (1) CA2368537A1 (de)
CO (1) CO5140098A1 (de)
CZ (1) CZ20012976A3 (de)
DE (1) DE60010662T2 (de)
DK (1) DK1152753T3 (de)
ES (1) ES2220411T3 (de)
GB (1) GB9903759D0 (de)
HU (1) HUP0200852A3 (de)
ID (1) ID29437A (de)
IL (1) IL144061A (de)
MY (1) MY126768A (de)
NO (1) NO20013987D0 (de)
NZ (1) NZ513526A (de)
PE (1) PE20001545A1 (de)
PL (1) PL349856A1 (de)
PT (1) PT1152753E (de)
RU (1) RU2249454C2 (de)
SK (1) SK11842001A3 (de)
TR (1) TR200102110T2 (de)
TW (1) TWI229601B (de)
WO (1) WO2000048587A1 (de)
ZA (1) ZA200105391B (de)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9616237D0 (en) 1996-08-01 1996-09-11 Norton Healthcare Ltd Aerosol formulations
GB2388843B (en) * 1999-09-11 2004-03-03 Glaxo Group Ltd A metered dose inhaler containing a pharmaceutical formulation of fluticasone propionate
FR2798290B1 (fr) 1999-09-11 2003-09-12 Glaxo Group Ltd Formulation pharmaceutique de propionate de fluticasone
GB2392915B (en) * 1999-09-11 2004-04-28 Glaxo Group Ltd Pharmaceutical formulation of fluticasone propionate
AU2001252350A1 (en) * 2000-04-13 2001-10-30 Innovata Biomed Limited Medicaments for treating respiratory disorders comprising formoterol and fluticasone
GB0009591D0 (en) * 2000-04-18 2000-06-07 Glaxo Group Ltd Medical combinations
GB0012260D0 (en) 2000-05-19 2000-07-12 Astrazeneca Ab Novel composition
US6759398B2 (en) * 2000-08-05 2004-07-06 Smithkline Beecham Corporation Anti-inflammatory androstane derivative
FI20002216A0 (fi) 2000-10-06 2000-10-06 Orion Yhtymae Oyj Yhdistelmäpartikkelit astman hoitoon
FI20002215A0 (fi) 2000-10-06 2000-10-06 Orion Yhtymae Oyj Yhdistelmäpartikkelit
PL365736A1 (en) * 2001-02-06 2005-01-10 Innovata Biomed Limited Bimodal dry powder formulation for inhalation
GB0106031D0 (en) * 2001-03-12 2001-05-02 Glaxo Group Ltd Use
PT1372608E (pt) * 2001-03-30 2008-01-04 Jagotec Ag Formulações de aerossol médicas
US6667344B2 (en) 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
US20030055026A1 (en) * 2001-04-17 2003-03-20 Dey L.P. Formoterol/steroid bronchodilating compositions and methods of use thereof
US7931022B2 (en) 2001-10-19 2011-04-26 Respirks, Inc. Method and apparatus for dispensing inhalator medicament
EP1757281A3 (de) * 2002-02-04 2009-07-15 Glaxo Group Limited Zubereitung zur Inhalation enthaltend ein Glucocorticoid und einen Beta 2-Adrenorezeptor Agonisten
JP2005523268A (ja) † 2002-02-04 2005-08-04 グラクソ　グループ　リミテッド グルココルチコイドおよびβ２−アドレナリン受容体アゴニストを含む吸入用製剤
GB2389530B (en) 2002-06-14 2007-01-10 Cipla Ltd Pharmaceutical compositions
GB0219511D0 (en) * 2002-08-21 2002-10-02 Norton Healthcare Ltd Method of preparing dry powder inhalation compositions
AU2003269989B8 (en) * 2002-08-21 2009-11-12 Norton Healthcare Ltd. Inhalation composition
US20050158248A1 (en) * 2002-08-21 2005-07-21 Xian-Ming Zeng Method of preparing dry powder inhalation compositions
JP4744876B2 (ja) * 2002-08-21 2011-08-10 ノートン・ヘルスケアー リミテッド 乾燥粉末吸入組成物の製造方法
AU2003263717A1 (en) * 2002-09-25 2004-04-19 Astrazeneca Ab A COMBINATION OF A LONG-ACTING Beta2-AGONIST AND A GLUCOCORTICOSTEROID IN THE TREATMENT OF FIBROTIC DISEASES
SE527069C2 (sv) 2003-06-19 2005-12-13 Mederio Ag Förfarande och anordning för administrering av läkemedelspulver
SE527189C2 (sv) * 2003-06-19 2006-01-17 Microdrug Ag Inhalatoranordning samt kombinerade doser för formaterol och ett antikolinergiskt medel
SE527200C2 (sv) * 2003-06-19 2006-01-17 Microdrug Ag Inhalatoranordning samt kombinerade doser av formaterol och fluticason
SE526850C2 (sv) * 2003-06-19 2005-11-08 Microdrug Ag Farmaceutisk kombinerad torr pulverdos separerade på gemensam dosbädd
SE526509C2 (sv) * 2003-06-19 2005-09-27 Microdrug Ag Kombinerade doser av formoterol och budesonid separerade på en gemensam dosbädd
TWI359675B (en) 2003-07-10 2012-03-11 Dey L P Bronchodilating β-agonist compositions
GB0323685D0 (en) * 2003-10-09 2003-11-12 Jagotec Ag Improvements in or relating to organic compounds
GB0323684D0 (en) 2003-10-09 2003-11-12 Jagotec Ag Improvements in or relating to organic compounds
RU2431501C2 (ru) * 2005-07-14 2011-10-20 Липотера, Инк. Липолитические составы с пролонгированным высвобождением для локального лечения отложения жировых тканей
GB0617171D0 (en) * 2006-08-31 2006-10-11 Generics Uk Ltd Novel compositions and methods
WO2008137446A1 (en) * 2007-05-03 2008-11-13 Trustees Of Boston University Methods and compositions for the treatment of respiratory disease
SI3106149T1 (sl) * 2009-05-29 2020-07-31 Pearl Therapeutics, Inc. Sestavki za pljučno dostavo muskarinskih antagonistov z dolgotrajnim delovanjem in agonistov beta-2 adrenergičnega receptorja z dolgotrajnim delovanjem in povezani postopki in sistemi
US8815258B2 (en) 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
GB0918150D0 (en) * 2009-10-16 2009-12-02 Jagotec Ag Improved formulations
GB0918149D0 (en) 2009-10-16 2009-12-02 Jagotec Ag Improved medicinal aerosol formulation
WO2011093811A2 (en) * 2010-01-29 2011-08-04 Mahmut Bilgic Pharmaceutical preparations comprising formoterol and fluticasone
KR20140025308A (ko) * 2010-10-12 2014-03-04 시플라 리미티드 약학 조성물
MX2013013440A (es) * 2011-05-17 2014-06-05 Pearl Therapeutics Inc Composiciones, metodos y sistemas para suministro respiratorio de dos o mas agentes activos.
KR20150002774A (ko) * 2012-04-11 2015-01-07 시플라 리미티드 아르포르모테롤 및 플루티카손 푸로에이트를 포함하는 약학 조성물
HK1219059A1 (zh) 2013-03-15 2017-03-24 珍珠治疗公司 用於微粒晶体材料的状态调节的方法和系统

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL95590A (en) * 1989-09-08 1996-06-18 Glaxo Group Ltd Medicinal preparations containing Salmetrol and Pluticasone Propionate
SE9302777D0 (sv) * 1993-08-27 1993-08-27 Astra Ab Process for conditioning substances
US5658549A (en) * 1991-12-12 1997-08-19 Glaxo Group Limited Aerosol formulations containing propellant 134a and fluticasone propionate
SK282826B6 (sk) * 1991-12-18 2002-12-03 Aktiebolaget Astra Farmaceutická kompozícia na podávanie inhaláciou s obsahom formoterolu a budesonidu a jej použitie
GB9426252D0 (en) * 1994-12-24 1995-02-22 Glaxo Group Ltd Pharmaceutical composition
SE9700135D0 (sv) * 1997-01-20 1997-01-20 Astra Ab New formulation
JP2001511160A (ja) * 1997-02-05 2001-08-07 ヤゴ リサーチ アクチェンゲゼルシャフト 医学用エアゾール配合物
CZ295460B6 (cs) * 1997-03-20 2005-08-17 Schering Corporation Způsob výroby aglomerátů a jednotková dávka farmakologicky aktivní látky je obsahující

Also Published As

Publication number Publication date
IL144061A0 (en) 2002-04-21
DK1152753T3 (da) 2004-08-16
MY126768A (en) 2006-10-31
CN1339965A (zh) 2002-03-13
EP1152753A1 (de) 2001-11-14
PE20001545A1 (es) 2001-01-29
KR20010102205A (ko) 2001-11-15
HUP0200852A3 (en) 2004-04-28
NO20013987L (no) 2001-08-16
DE60010662D1 (de) 2004-06-17
ES2220411T3 (es) 2004-12-16
US20050287079A1 (en) 2005-12-29
US20020103260A1 (en) 2002-08-01
EP1152753B1 (de) 2004-05-12
NZ513526A (en) 2004-01-30
BR0008276A (pt) 2001-11-06
JP2002537249A (ja) 2002-11-05
US20100034890A1 (en) 2010-02-11
GB9903759D0 (en) 1999-04-14
CO5140098A1 (es) 2002-03-22
IL144061A (en) 2005-12-18
US20040101487A1 (en) 2004-05-27
AR022609A1 (es) 2002-09-04
DE60010662T2 (de) 2005-05-19
ID29437A (id) 2001-08-30
NO20013987D0 (no) 2001-08-16
AU758999B2 (en) 2003-04-03
CZ20012976A3 (cs) 2001-11-14
TWI229601B (en) 2005-03-21
HK1042429A1 (en) 2002-08-16
TR200102110T2 (tr) 2001-10-22
PL349856A1 (en) 2002-09-23
CA2368537A1 (en) 2000-08-24
AU2911500A (en) 2000-09-04
RU2249454C2 (ru) 2005-04-10
ZA200105391B (en) 2002-06-21
SK11842001A3 (sk) 2001-12-03
HUP0200852A2 (en) 2002-08-28
KR20070104955A (ko) 2007-10-29
WO2000048587A1 (en) 2000-08-24
PT1152753E (pt) 2004-09-30

Similar Documents

Publication Publication Date Title
ATE266393T1 (de) Kombinationen von formoterol und fluticasonpropionat für asthma
EE04297B1 (et) Budesoniidi ja formoterooli uus kasutamine
NO20006253D0 (no) Anvendelse av et preparat omfattende formoterol og budesonid for forebyggelse eller behandling av en akutt astmatilstand
DE69838984D1 (de) Risikoabschätzung für chronische atemwegserkrankungen und anwendungen
DE69908339D1 (de) Endgerät für bibliotheken und dergleichen
ATE428428T1 (de) Kombination von azelastine und fluticasone
FI964634L (fi) Flutikasonipropionaattiformuloita
ATE347391T1 (de) Dosierinhalator für fluticasonepropionat
DE69940137D1 (de) Blattförmiges Adsorptionsmittel für Gase und Luftreinigungsfilter
DE69837795D1 (de) Zentrifugalkompressor und wellendichtung
NO20030899D0 (no) Anvendelse av salmeterol og fluticasonpropionat kombinasjon
PL358375A1 (en) Medicaments for treating respiratory disorders comprising formoterol and fluticasone
PT1140110E (pt) Clatratos de desidroepiandrosterona e correspondentes composicoes farmaceuticas
DE69932653D1 (de) Dielektrisches Filter und dielektrischer Duplexer
SI1152753T1 (en) Combinations of formoterol and fluticasone propionate for asthma
IT1305022B1 (it) Nastro bordato e procedimento per la bordatura dei suoi orli
SI1156790T1 (en) Combinations of formoterol and mometasone furoate
ID30541A (id) Peptida-peptida kecil dan penggunannya pada penyembuhan asma dan radang
DE59506201D1 (de) Schwingungsdämpfer für schwingungsgefährdete Bauteile und Bauwerke
SI1085877T1 (sl) Uporaba sestavka, ki obsega formoterol in budezonid, za preprečevanje ali zdravljenje akutnega stanja
DE69517088D1 (de) Methode für klebende Verbindung und Einrichtung dafür

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1152753

Country of ref document: EP

RZN Patent revoked